#BEGIN_DRUGCARD DB00199

# AHFS_Codes:
08:12.12.04
34:00.00
52:04.04

# ATC_Codes:
D10AF02
J01FA01
S01AA17

# Absorption:
Orally administered erythromycin base and its salts are readily absorbed in the microbiologically active form. Topical application of the ophthalmic ointment to the eye may result in absorption into the cornea and aqueous humor.

# Biotransformation:
Hepatic. Extensively metabolized - after oral administration, less than 5% of the administered dose can be recovered in the active form in the urine. Erythromycin is partially metabolized by CYP3A4 resulting in numerous drug interactions.

# Brand_Mixtures:
Sans-Acne Solution (Alcohol Anhydrous + Erythromycin)
Staticin Lot (Alcohol Anhydrous + Erythromycin + Laureth 4)
Stievamycin Forte Gel (Erythromycin + Tretinoin)
Stievamycin Gel (Erythromycin + Tretinoin)
T-Stat Lot (Alcohol Anhydrous + Erythromycin)
T-Stat Pad-Lot (Alcohol Anhydrous + Erythromycin)

# Brand_Names:
Abboticin
Abomacetin
Ak-mycin
Akne-Mycin
Aknin
Benzamycin
Benzamycin Pak
Bristamycin
Dotycin
Dumotrycin
E-Base
E-Glades
E-Mycin
E-Solve 2
EMU
Emgel
Eritrocina
Ermycin
Ery-Sol
Ery-Tab
Eryc
Eryc 125
Eryc Sprinkles
Erycen
Erycette
Erycin
Erycinum
Eryderm
Erygel
Erymax
Erypar
Erythra-Derm
Erythro
Erythro-Statin
Erythrogran
Erythroguent
Erythromast 36
Erythromid
Erythromycin A
Erythromycin B
Ethril 250
Ilocaps
Ilosone
Ilotycin
Ilotycin Gluceptate
IndermRetcin
Kesso-Mycin
Mephamycin
Pantomicina
Pfizer-e
Propiocine
R-P Mycin
Robimycin
Sansac
Stiemycin
Taimoxin-F
Theramycin Z
Torlamicina
Wemid
Wyamycin S

# CAS_Registry_Number:
114-07-8

# ChEBI_ID:
48923

# Chemical_Formula:
C37H67NO13

# Chemical_IUPAC_Name:
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2237041

# Description:
Erythromycin is a macrolide antibiotic produced by Streptomyces erythreus. It inhibits bacterial protein synthesis by binding to bacterial 50S ribosomal subunits; binding inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.  Erythromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.

# Dosage_Forms:
Capsule, coated	Oral
Liquid	Dental
Liquid	Oral
Ointment	Ophthalmic
Powder	Intravenous
Powder	Oral
Powder, for solution	Intravenous
Powder, for solution	Oral
Powder, for suspension	Oral
Suspension	Oral
Tablet	Oral

# Drug_Category:
Anti-Bacterial Agents
Macrolides

# Drug_Interactions:
Acenocoumarol	The macrolide, erythromycin, may increase the anticoagulant effect of acenocoumarol.
Alfentanil	The macrolide, erythromycin, may increase the effect and toxicity of alfentanil.
Alprazolam	The macrolide, erythromycin, may increase the effect of the benzodiazepine, alprazolam.
Aminophylline	The macrolide, erythromycin, may increase the effect and toxicity of the theophylline derivative, aminophylline.
Amiodarone	Increased risk of cardiotoxicity and arrhythmias
Anisindione	The macrolide, erythromycin, may increase the anticoagulant effect of anisindione.
Aprepitant	Erythromycin, a moderate CYP3A4 inhibitor, may increase the effect and toxicity of aprepitant.
Artemether	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
Astemizole	Increased risk of cardiotoxicity and arrhythmias
Atorvastatin	The macrolide, erythromycin, may increase the toxicity of the statin, atorvastatin.
Avanafil	Co-administration with the moderate CYP3A4 inhibitor erythromycin resulted in an approximate 3.6-fold increase in AUC0-inf and 2.0-fold increase in Cmax of avanafil.
Bendamustine	Decreases metabolism, thus decreasing the effects of bendamustine.
Bretylium	Increased risk of cardiotoxicity and arryhthmias
Bromazepam	Erythromcyin may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if erythromycin is initiated, discontinued or dose changed. Dosage adjustments may be required.
Bromocriptine	Erythromycin increases serum levels of bromocriptine
Buspirone	The macrolide, erythromycin, may increase the effect and toxicity of buspirone.
Cabergoline	Erythromycin increases serum levels and toxicity of cabergoline
Carbamazepine	The macrolide, erythromycin, may increase the effect of carbamazepine.
Cerivastatin	The macrolide, erythromycin, may increase the toxicity of the statin, cerivastatin.
Cilostazol	Erythromycin increases the effect of cilostazol
Cinacalcet	The macrolide, erythromycin, may increase the serum concentration and toxicity of cinacalcet.
Cisapride	Increased risk of cardiotoxicity and arrhythmias
Citalopram	Possible serotoninergic syndrome with this combination
Clozapine	Erythromycin increases the effect of clozapine
Colchicine	Severe colchicine toxicity can occur
Cyclosporine	The macrolide, erythromycin, may increase the effect of cyclosporine.
Diazepam	The macrolide, erythromycin, may increase the effect of the benzodiazepine, diazepam.
Dicumarol	The macrolide, erythromycin, may increase the anticoagulant effect of dicumarol..
Digoxin	The macrolide, erythromycin, may increase the effect of digoxin in 10% of patients.
Dihydroergotamine	Possible ergotism and severe ischemia with this combination
Dihydroergotoxine	Possible ergotism and severe ischemia with this combination
Disopyramide	Increased risk of cardiotoxicity and arrhythmias
Docetaxel	Erythromycin may increase the serum levels and toxicity of docetaxel.
Dofetilide	Increased risk of cardiotoxicity and arrhythmias
Dyphylline	The macrolide, erythromycin, may increase the effect and toxicity of the theophylline derivative, dyphylline.
Eletriptan	The macrolide, erythromycin, may increase the effect and toxicity of eletriptan.
Eltrombopag	Affects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect.
Eplerenone	This CYP3A4 inhibitor increases the effect and toxicity of eplerenone
Ergonovine	Possible ergotism and severe ischemia with this combination
Ergotamine	Possible ergotism and severe ischemia with this combination
Erlotinib	This CYP3A4 inhibitor increases levels/toxicity of erlotinib
Everolimus	The macrolide, erythromycin, may increase the serum concentration and toxicity of everolimus.
Felodipine	Erythromycin increases the effect of felodipine
Fluoxetine	Possible serotoninergic syndrome with this combination
Gefitinib	This CYP3A4 inhibitor increases levels/toxicity of gefitinib
Grepafloxacin	Increased risk of cardiotoxicity and arrhythmias
Imatinib	The macrolide, erythromycin, may increase the serum concentration of imatinib.
Indacaterol	Strong inhibitors of CYP3A4 may increase levels of indacaterol. Monitor closely for adverse events.
Itraconazole	The macrolide, erythromycin, may increase the effect and toxicity of itraconazole.
Ivacaftor	Moderate CYP3A4 inhibitors may increase levels of ivacaftor. Consider dose reduction.
Levofloxacin	Increased risk of cardiotoxicity and arrhythmias
Lincomycin	Possible antagonism of action with this combination.
Lovastatin	The macrolide, erythromycin, may increase the toxicity of the statin, lovastatin.
Lumefantrine	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
Mesoridazine	Increased risk of cardiotoxicity and arrhythmias
Methylergonovine	Possible ergotism and severe ischemia with this combination
Methylprednisolone	The macrolide, erythromycin, may increase the effect of corticosteroid, methylprednisolone.
Methysergide	Possible ergotism and severe ischemia with this combination
Midazolam	The macrolide, erythromycin, may increase the effect of the benzodiazepine, midazolam.
Moxifloxacin	Increased risk of cardiotoxicity and arrhythmias
Oxtriphylline	The macrolide, erythromycin, may increase the effect and toxicity of the theophylline derivative, oxtriphylline.
Pazopanib	Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy.
Pimozide	Increased risk of cardiotoxicity and arrhythmias
Pitavastatin	Erythromycin decreases metabolism of pitavastatin. Do not exceed 1 mg per day of pitavastatin or use alternative therapy.
Quetiapine	The macrolide, erythromycin, may increase the effect and toxicity of quetiapine.
Quinidine	Increased risk of cardiotoxicity and arrhythmias
Quinidine barbiturate	Increased risk of cardiotoxicity and arrhythmias
Quinupristin	This combination presents an increased risk of toxicity
Ranolazine	Increased levels of ranolazine - risk of toxicity
Repaglinide	The macrolide, erythromycin, may increase the effect of repaglinide.
Rifabutin	The rifamycin, rifabutin, may decrease the effect of the macrolide, erythromycin.
Rifampin	The rifamycin, rifampin, may decrease the effect of the macrolide, erythromycin.
Ritonavir	Increased toxicity of both agents
Roflumilast	Increases roflumilast levels.
Saxagliptin	Erythromycin is an inhibitor of CYP3A4 which increases exposure of saxagliptin. Decrease dose of saxagliptin to 2.5 mg per day.
Sertraline	Possible serotoninergic syndrome with this combination
Sibutramine	Erythromycin increases the effect and toxicity of sibutramine
Sildenafil	The macrolide, erythromycin, may increase the effect and toxicity of sildenafil.
Silodosin	Erythromycin is a moderate inhibitor of CYP3A4 and inhibits P-glycoprotein thus increasing the potential for adverse effects
Simvastatin	The macrolide, erythromycin, may increase the toxicity of the statin, simvastatin.
Sirolimus	The macrolide, erythromycin, may increase the serum concentration of sirolimus.
Sotalol	Increased risk of cardiotoxicity and arrhythmias
Sparfloxacin	Increased risk of cardiotoxicity and arrhythmias
Tacrolimus	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. The macrolide antibiotic, erythromycin, may also increase the blood concentration of tacrolimus.
Tamsulosin	Erythromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Erythromycin is initiated, discontinued, or dose changed.
Telithromycin	Telithromycin may reduce clearance of Erythromycin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Erythromycin if Telithromycin is initiated, discontinued or dose changed.
Terfenadine	Increased risk of cardiotoxicity and arrhythmias
Theophylline	The macrolide, erythromycin, may increase the effect and toxicity of theophylline.
Thioridazine	Increased risk of cardiotoxicity and arrhythmias
Thiothixene	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
Tolvaptan	Erythromycin is a moderate inhibitor of CYP3A4 and will considerably increase tolvaptan serum concentrations
Topotecan	The p-glycoprotein inhibitor, Erythromycin, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
Toremifene	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
Tramadol	Erythromycin may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
Trazodone	The CYP3A4 inhibitor, Erythromycin , may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Erythromycin is initiated, discontinued or dose changed.
Triazolam	The macrolide, erythromycin, may increase the effect of the benzodiazepine, triazolam.
Trimipramine	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
Valproic Acid	The macrolide antibiotic, Erythromycin, may increase the serum concentratin of Valproic acid. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Erythromycin is initiated, discontinued or dose changed.
Vardenafil	Erythromycin, a moderate CYP3A4 inhibitor, may reduce the metabolism and clearance of vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of vardenafil if erythromycin is initiated, discontinued or dose changed.
Verapamil	Erythromycin, a moderate CYP3A4 inhibitor, may increase the serum concentration of veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Monitor for changes in the therapeutic/adverse effects of verapamil if erythromycin is initiated, discontinued or dose changed.
Vinblastine	Erythromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the vinblastine serum concentration and distribution in certain cells. Consider alternate therapy to avoid vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of vinblastine if erythromycin is initiated, discontinued or dose changed.
Vincristine	Erythromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vincristine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Erythromycin is initiated, discontinued or dose changed.
Vinorelbine	Erythromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinorelbine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Erythromycin is initiated, discontinued or dose changed.
Vismodegib	P-glycoprotein inhibitors may increase the chance of adverse drug reactions.
Voriconazole	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of erythromycin by decreasing its metabolism. Erythromycin may increase the serum concentration of voriconazole by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed.
Vorinostat	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Warfarin	The macrolide, erythromycin, may increase the anticoagulant effect of warfarin.
Zafirlukast	Erythromycin may decrease the serum concentration and effect of zafirlukast.
Ziprasidone	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
Zopiclone	The macrolide antibiotic, erythromycin, may increase the serum concentration of zopiclone. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if erythromycin is initiated, discontinued or dose changed.
Zuclopenthixol	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).

# Drug_Reference:
11294369	Kanazawa S, Ohkubo T, Sugawara K: The effects of grapefruit juice on the pharmacokinetics of erythromycin. Eur J Clin Pharmacol. 2001 Jan-Feb;56(11):799-803.
12789122	Ogwal S, Xide TU: Bioavailability and stability of erythromycin delayed release tablets. Afr Health Sci. 2001 Dec;1(2):90-6.
17585116	Okudaira T, Kotegawa T, Imai H, Tsutsumi K, Nakano S, Ohashi K: Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. J Clin Pharmacol. 2007 Jul;47(7):871-6.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
-5.43

# Experimental_LogP_Hydrophobicity:
3.06

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Slightly soluble (1.44 mg/L)

# Food_Interactions:
Avoid alcohol.
Take on empty stomach: 1 hour before or 2 hours after meals.
Take with a full glass of water Avoid taking with grapefruit juice.

# GenBank_ID:
Not Available

# Generic_Name:
Erythromycin

# HET_ID:
ERY

# Half_Life:
0.8 - 3 hours

# InChI_Identifier:
InChI=1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1

# InChI_Key:
InChIKey=ULGZDMOVFRHVEP-RWJQBGPGSA-N

# Indication:
For use in the treatment of infections caused by susceptible strains of microorganisms in the following diseases: respiratory tract infections (upper and lower) of mild to moderate degree, pertussis (whooping cough), as adjunct to antitoxin in infections due to <i>Corynebacterium diphtheriae</i>, in the treatment of infections due to <i>Corynebacterium minutissimum</i>, intestinal amebiasis caused by <i>Entamoeba histolytica</i>, acute pelvic inflammatory disease caused by <i>Neisseria gonorrhoeae</i>, skin and soft tissue infections of mild to moderate severity caused by <i>Streptococcus pyogenes</i> and <i>Staphylococcus aureus</i>, primary syphilis caused by <i>Treponema pallidum</i>, infections caused by <i>Chlamydia trachomatis</i>, nongonococcal urethritis caused by <i>Ureaplasma urealyticum</i>, and Legionnaires' disease caused by <i>Legionella pneumophila</i>.

# KEGG_Compound_ID:
C01912

# KEGG_Drug_ID:
D00140

# LIMS_Drug_ID:
199

# Mechanism_Of_Action:
Erythromycin acts by penetrating the bacterial cell membrane and reversibly binding to the 50 S subunit of bacterial ribosomes or near the &ldquo;P&rdquo; or donor site so that binding of tRNA (transfer RNA) to the donor site is blocked. Translocation of peptides from the &ldquo;A&rdquo; or acceptor site to the &ldquo;P&rdquo; or donor site is prevented, and subsequent protein synthesis is inhibited. Erythromycin is effective only against actively dividing organisms. The exact mechanism by which erythmromycin reduces lesions of acne vulgaris is not fully known: however, the effect appears to be due in part to the antibacterial activity of the drug.

# Melting_Point:
191 °C

# Molecular_Weight_Avg:
733.9268

# Molecular_Weight_Mono:
733.461241235

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/ery1163.shtml

# Pathways:
Erythromycin Pathway	SMP00250

# PharmGKB_ID:
PA449493

# Pharmacology:
Erythromycin is produced by a strain of Streptomyces erythraeus and belongs to the macrolide group of antibiotics. After absorption, erythromycin diffuses readily into most body fluids. In the absence of meningeal inflammation, low concentrations are normally achieved in the spinal fluid, but the passage of the drug across the blood-brain barrier increases in meningitis. Erythromycin is excreted in breast milk. The drug crosses the placental barrier with fetal serum drug levels reaching 5 - 20% of maternal serum concentrations. Erythromycin is not removed by peritoneal dialysis or hemodialysis.

# Predicted_LogP_Hydrophobicity:
2.37

# Predicted_LogS:
-3.2

# Predicted_Water_Solubility:
4.59e-01 g/l

# Primary_Accession_No:
DB00199

# Protein_Binding:
Erythromycin is largely bound to plasma proteins, ranging from 75 - 95% binding depending on the form.

# PubChem_Compound_ID:
12560

# PubChem_Substance_ID:
46508487

# RxList_Link:
http://www.rxlist.com/cgi/generic/erithrom.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00953

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
EM
Erythrocin Stearate
Erythromycin Stearate
Erythromycin ethylsuccinate
Erythromycin glucoheptonate
Erythromycin lactobionate
Erythromycin oxime

# Synthesis_Reference:
Not Available

# Toxicity:
Symptoms of overdose include diarrhea, nausea, stomach cramps, and vomiting.

# Update_Date:
2013-02-08 16:19:10 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Erythromycin

# pKa_Isoelectric_Point:
8.88 (at 25 °C)

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP3A5

# Phase_1_Metabolizing_Enzyme_1_ID:
4118

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 3A5

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 3A5
MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNVLSYRQGLWKF
DTECYKKYGKMWGTYEGQLPVLAITDPDVIRTVLVKECYSVFTNRRSLGPVGFMKSAISL
AEDEEWKRIRSLLSPTFTSGKLKEMFPIIAQYGDVLVRNLRREAEKGKPVTLKDIFGAYS
MDVITGTSFGVNIDSLNNPQDPFVESTKKFLKFGFLDPLFLSIILFPFLTPVFEALNVSL
FPKDTINFLSKSVNRMKKSRLNDKQKHRLDFLQLMIDSQNSKETESHKALSDLELAAQSI
IFIFAGYETTSSVLSFTLYELATHPDVQQKLQKEIDAVLPNKAPPTYDAVVQMEYLDMVV
NETLRLFPVAIRLERTCKKDVEINGVFIPKGSMVVIPTYALHHDPKYWTEPEEFRPERFS
KKKDSIDPYIYTPFGTGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLDTQG
LLQPEKPIVLKVDSRDGTLSGE

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P20815

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CYP1A2

# Phase_1_Metabolizing_Enzyme_2_ID:
4200

# Phase_1_Metabolizing_Enzyme_2_Name:
Cytochrome P450 1A2

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cytochrome P450 1A2
MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P05177

# Phase_1_Metabolizing_Enzyme_3_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_3_ID:
4512

# Phase_1_Metabolizing_Enzyme_3_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_3_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_3_SwissProt_ID:
P08684

# Phase_1_Metabolizing_Enzyme_4_Gene_Name:
CYP3A7

# Phase_1_Metabolizing_Enzyme_4_ID:
6107

# Phase_1_Metabolizing_Enzyme_4_Name:
Cytochrome P450 3A7

# Phase_1_Metabolizing_Enzyme_4_Protein_Sequence:
>Cytochrome P450 3A7
MDLIPNLAVETWLLLAVSLILLYLYGTRTHGLFKKLGIPGPTPLPFLGNALSFRKGYWTF
DMECYKKYRKVWGIYDCQQPMLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKNAISI
AEDEEWKRIRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKHVFGAYS
MDVITSTSFGVSIDSLNNPQDPFVENTKKLLRFNPLDPFVLSIKVFPFLTPILEALNITV
FPRKVISFLTKSVKQIKEGRLKETQKHRVDFLQLMIDSQNSKDSETHKALSDLELMAQSI
IFIFAGYETTSSVLSFIIYELATHPDVQQKVQKEIDTVLPNKAPPTYDTVLQLEYLDMVV
NETLRLFPVAMRLERVCKKDVEINGMFIPKGVVVMIPSYVLHHDPKYWREPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALVNMKLALVRVLQNFSFKPCKETQIPLKLRFG
GLLLTEKPIVLKAESRDETVSGA

# Phase_1_Metabolizing_Enzyme_4_SwissProt_ID:
P24462

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11677599	Schlunzen F, Zarivach R, Harms J, Bashan A, Tocilj A, Albrecht R, Yonath A, Franceschi F: Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21.
11698379	Garza-Ramos G, Xiong L, Zhong P, Mankin A: Binding site of macrolide antibiotics on the ribosome: new resistance mutation identifies a specific interaction of ketolides with rRNA. J Bacteriol. 2001 Dec;183(23):6898-907.
3122849	Moazed D, Noller HF: Chloramphenicol, erythromycin, carbomycin and vernamycin B protect overlapping sites in the peptidyl transferase region of 23S ribosomal RNA. Biochimie. 1987 Aug;69(8):879-84.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Not Available

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
Not Available

# Drug_Target_1_Gene_Sequence:
>23S rRNA sequence
GATTAAGTTATTAAGGGCGCACGGTGGATGCCTTGGCACTAGAAGCCGATGAAGGACGTT
ACTAACGACGATATGCTTTGGGGAGCTGTAAGTAAGCTTTGATCCAGAGATTTCCGAATG
GGGAAACCCAGCATGAGTTATGTCATGTTATCGATATGTGAATACATAGCATATCAGAAG
GCACACCCGGAGAACTGAAACATCTTAGTACCCGGAGGAAGAGAAAGAAAATTCGATTCC
CTTAGTAGCGGCGAGCGAAATGGGAAGAGCCCAAACCAACAAGCTTGCTTGTTGGGGTTG
TAGGACACTCTATACGGAGTTACAAAGGACGACATTAGACGAATCATCTGGAAAGATGAA
TCAAAGAAGGTAATAATCCTGTAGTCGAAAATGTTGTCTCTCTTGAGTGGATCCTGAGTA
CGACGGAGCACGTGAAATTCCGTCGGAATCTGGGAGGACCATCTCCTAAGGCTAAATACT
CTCTAGTGACCGATAGTGAACCAGTACCGTGAGGGAAAGGTGAAAAGCACCCCGGAAGGG
GAGTGAAATAGAACCTGAAACCGTGTGCTTACAAGTAGTCAGAGCCCGTTAATGGGTGAT
GGCGTGCCTTTTGTAGAATGAACCGGCGAGTTACGATTTGATGCAAGGTTAAGCAGTAAA
TGTGGAGCCGTAGCGAAAGCGAGTCTGAATAGGGCGTTTAGTATTTGGTCGTAGACCCGA
AACCAGGTGATCTACCCTTGGTCAGGTTGAAGTTCAGGTAACACTGAATGGAGGACCGAA
CCGACTTACGTTGAAAAGTGAGCGGATGAACTGAGGGTAGCGGAGAAATTCCAATCGAAC
CTGGAGATAGCTGGTTCTCTCCGAAATAGCTTTAGGGCTAGCCTCAAGTGATGATTATTG
GAGGTAGAGCACTGTTTGGACGAGGGGCCCCTCTCGGGTTACCGAATTCAGACAAACTCC
GAATGCCAATTAATTTAACTTGGGAGTCAGAACATGGGTGATAAGGTCCGTGTTCGAAAG
GGAAACAGCCCAGACCACCAGCTAAGGTCCCAAAATATATGTTAAGTGGAAAAGGATGTG
GCGTTGCCCAGACAACTAGGATGTTGGCTTAGAAGCAGCCATCATTTAAAGAGTGCGTAA
TAGCTCACTAGTCGAGTGACACTGCGCCGAAAATGTACCGGGGCTAAACATATTACCGAA
GCTGTGGATTGTCCTTTGGACAATGGTAGGAGAGCGTTCTAAGGGCGTTGAAGCATGATC
GTAAGGACATGTGGAGCGCTTAGAAGTGAGAATGCCGGTGTGAGTAGCGAAAGACGGGTG
AGAATCCCGTCCACCGATTGACTAAGGTTTCCAGAGGAAGGCTCGTCCGCTCTGGGTTAG
TCGGGTCCTAAGCTGAGGCCGACAGGCGTAGGCGATGGATAACAGGTTGATATTCCTGTA
CCACCTATAATCGTTTTAATCGATGGGGGGACGCAGTAGGATAGGCGAAGCGTGCGATTG
GATTGCACGTCTAAGCAGTAAGGCTGAGTATTAGGCAAATCCGGTACTCGTTAAGGCTGA
GCTGTGATGGGGAGAAGACATTGTGTCTTCGAGTCGTTGATTTCACACTGCCGAGAAAAG
CCTCTAGATAGAAAATAGGTGCCCGTACCGCAAACCGACACAGGTAGTCAAGATGAGAAT
TCTAAGGTGAGCGAGCGAACTCTCGTTAAGGAACTCGGCAAAATGACCCCGTAACTTCGG
GAGAAGGGGTGCTCTTTAGGGTTAACGCCCAGAAGAGCCGCAGTGAATAGGCCCAAGCGA
CTGTTTATCAAAAACACAGGTCTCTGCTAAACCGTAAGGTGATGTATAGGGGCTGACGCC
TGCCCGGTGCTGGAAGGTTAAGAGGAGTGGTTAGCTTCTGCGAAGCTACGAATCGAAGCC
CCAGTAAACGGCGGCCGTAACTATAACGGTCCTAAGGTAGCGAAATTCCTTGTCGGGTAA
GTTCCGACCCGCACGAAAGGCGTAACGATTTGGGCACTGTCTCAACGAGAGACTCGGTGA
AATCATAGTACCTGTGAAGATGCAGGTTACCCGCGACAGGACGGAAAGACCCCGTGGAGC
TTTACTGTAGCCTGATATTGAAATTCGGCACAGCTTGTACAGGATAGGTAGGAGCCTTTG
AAACGTGAGCGCTAGCTTACGTGGAGGCGCTGGTGGGATACTACCCTAGCTGTGTTGGCT
TTCTAACCCGCACCACTTATCGTGGTGGGAGACAGTGTCAGGCGGGCAGTTTGACTGGGG
CGGTCGCCTCCTAAAAGGTAACGGAGGCGCTCAAAGGTTCCCTCAGAATGGTTGGAAATC
ATTCATAGAGTGTAAAGGCATAAGGGAGCTTGACTGCGAGACCTACAAGTCGAGCAGGGT
CGAAAGACGGACTTAGTGATCCGGTGGTTCCGCATGGAAGGGCCATCGCTCAACGGATAA
AAGCTACCCCGGGGATAACAGGCTTATCTCCCCCAAGAGTTCACATCGACGGGGAGGTTT
GGCACCTCGATGTCGGCTCATCGCATCCTGGGGCTGTAGTCGGTCCCAAGGGTTGGGCTG
TTCGCCCATTAAAGCGGTACGCGAGCTGGGTTCAGAACGTCGTGAGACAGTTCGGTCCCT
ATCCGTCGTGGGCGTAGGAAATTTGAGAGGAGCTGTCCTTAGTACGAGAGGACCGGGATG
GACATACCTCTGGTGTACCAGTTGTCGTGCCAACGGCATAGCTGGGTAGCTATGTGTGGA
CGGGATAAGTGCTGAAAGCATCTAAGCATGAAGCCCCCCTCAAGATGAGATTTCCCAACT
TCGGTTATAAGATCCCTCAAAGATGATGAGGTTAATAGGTTCGAGGTGGAAGCATGGTGA
CATGTGGAGCTGACGAATACTAATCGATCGAAGACTTAATCAA

# Drug_Target_1_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_1_General_References:
11249571	Barrett JF: Linezolid Pharmacia Corp. Curr Opin Investig Drugs. 2000 Oct;1(2):181-7.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
884

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
Not Available

# Drug_Target_1_Name:
23S rRNA

# Drug_Target_1_Number_of_Residues:
0

# Drug_Target_1_PDB_ID:
1EMI

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
Not Available

# Drug_Target_1_Protein_Sequence:
Not Available

# Drug_Target_1_Reaction:
tRNA-aminoacid + ATP + polypeptide(n) = polypeptide(n+1) + ADP

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
In prokaryotes, the 23S rRNA is part of the large subunit (the 50S) that joins with the 30S small subunit to create the functional 70S ribosome. The ribosome is comprised of 3 RNAs: the 23S, the 16S and the 5S ribosomal RNAs. The 23S and the 5S associate with their respective proteins to make up the large subunit of the ribosome, while the 16S RNA associates with its proteins to make up the small subunit.

# Drug_Target_1_SwissProt_ID:
Not Available

# Drug_Target_1_SwissProt_Name:
Not Available

# Drug_Target_1_Synonyms:
23S ribosomal ribonucleic acid

# Drug_Target_1_Theoretical_pI:
Not Available

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
12225755	Davydova N, Streltsov V, Wilce M, Liljas A, Garber M: L22 ribosomal protein and effect of its mutation on ribosome resistance to erythromycin. J Mol Biol. 2002 Sep 20;322(3):635-44.
12623020	Schlunzen F, Harms JM, Franceschi F, Hansen HA, Bartels H, Zarivach R, Yonath A: Structural basis for the antibiotic activity of ketolides and azalides. Structure. 2003 Mar;11(3):329-38.
15851032	Tu D, Blaha G, Moore PB, Steitz TA: Structures of MLSBK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance. Cell. 2005 Apr 22;121(2):257-70.
15996971	Rolain JM, Raoult D: Prediction of resistance to erythromycin in the genus Rickettsia by mutations in L22 ribosomal protein. J Antimicrob Chemother. 2005 Aug;56(2):396-8. Epub 2005 Jul 4.
16940070	Cagliero C, Mouline C, Cloeckaert A, Payot S: Synergy between efflux pump CmeABC and modifications in ribosomal proteins L4 and L22 in conferring macrolide resistance in Campylobacter jejuni and Campylobacter coli. Antimicrob Agents Chemother. 2006 Nov;50(11):3893-6. Epub 2006 Aug 28.
17014718	Halling SM, Jensen AE: Intrinsic and selected resistance to antibiotics binding the ribosome: analyses of Brucella 23S rrn, L4, L22, EF-Tu1, EF-Tu2, efflux and phylogenetic implications. BMC Microbiol. 2006 Oct 2;6:84.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
AE005174

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
rplV

# Drug_Target_2_Gene_Sequence:
>333 bp
TCAGCGATCGGACACAACCACAGTGATGTGGCTGGTGCGCTTCAGGATGCGATCTGCACG
ACCTTTTGCACGCGGCATAATGCGCTTCATGCTCGGGCCTTCGTCTACGAAAATTTTCGT
AACTTTCAGATCGTCAATGTCAGCGCCATCGTTGTGTTCAGCGTTAGCAATGGCAGATTC
CAGAACTTTCTTGACCAGTACAGCCGCTTTCTTGTTGGTGTAGGTCAAAATATCCAGAGC
CTGCGACACTTTCTTACCGCGAATCAGGTCAGCAACAAGGCGAACCTTCTGAGCAGAAGA
ACGAGCATGGCGATGTTTAGCGATAGTTTCCAT

# Drug_Target_2_General_Function:
Involved in structural constituent of ribosome

# Drug_Target_2_General_References:
11206551	Perna NT, Plunkett G 3rd, Burland V, Mau B, Glasner JD, Rose DJ, Mayhew GF, Evans PS, Gregor J, Kirkpatrick HA, Posfai G, Hackett J, Klink S, Boutin A, Shao Y, Miller L, Grotbeck EJ, Davis NW, Lim A, Dimalanta ET, Potamousis KD, Apodaca J, Anantharaman TS, Lin J, Yen G, Schwartz DC, Welch RA, Blattner FR: Genome sequence of enterohaemorrhagic Escherichia coli O157:H7. Nature. 2001 Jan 25;409(6819):529-33.
11258796	Hayashi T, Makino K, Ohnishi M, Kurokawa K, Ishii K, Yokoyama K, Han CG, Ohtsubo E, Nakayama K, Murata T, Tanaka M, Tobe T, Iida T, Takami H, Honda T, Sasakawa C, Ogasawara N, Yasunaga T, Kuhara S, Shiba T, Hattori M, Shinagawa H: Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 and genomic comparison with a laboratory strain K-12. DNA Res. 2001 Feb 28;8(1):11-22.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
4237

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
12226

# Drug_Target_2_Name:
50S ribosomal protein L22

# Drug_Target_2_Number_of_Residues:
110

# Drug_Target_2_PDB_ID:
1P86

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00237	Ribosomal_L22

# Drug_Target_2_Protein_Sequence:
>50S ribosomal protein L22
METIAKHRHARSSAQKVRLVADLIRGKKVSQALDILTYTNKKAAVLVKKVLESAIANAEH
NDGADIDDLKVTKIFVDEGPSMKRIMPRAKGRADRILKRTSHITVVVSDR

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
The globular domain of the protein is located near the polypeptide exit tunnel on the outside of the subunit, while an extended beta-hairpin is found that lines the wall of the exit tunnel in the center of the 70S ribosome (By similarity)

# Drug_Target_2_SwissProt_ID:
P61177

# Drug_Target_2_SwissProt_Name:
RL22_ECO57

# Drug_Target_2_Synonyms:
Not Available

# Drug_Target_2_Theoretical_pI:
10.98

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
12623020	Schlunzen F, Harms JM, Franceschi F, Hansen HA, Bartels H, Zarivach R, Yonath A: Structural basis for the antibiotic activity of ketolides and azalides. Structure. 2003 Mar;11(3):329-38.
15509870	O'Connor M, Gregory ST, Dahlberg AE: Multiple defects in translation associated with altered ribosomal protein L4. Nucleic Acids Res. 2004 Oct 27;32(19):5750-6. Print 2004.
15851032	Tu D, Blaha G, Moore PB, Steitz TA: Structures of MLSBK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance. Cell. 2005 Apr 22;121(2):257-70.
17014718	Halling SM, Jensen AE: Intrinsic and selected resistance to antibiotics binding the ribosome: analyses of Brucella 23S rrn, L4, L22, EF-Tu1, EF-Tu2, efflux and phylogenetic implications. BMC Microbiol. 2006 Oct 2;6:84.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
AE005174

# Drug_Target_3_GenBank_ID_Protein:
Not Available

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
rplD

# Drug_Target_3_Gene_Sequence:
>606 bp
TCATGCCAGCATCTCCTCAACTTGCTTAACAGCATCAGCAGTCATTACGACTTTGTCGAA
GGCGATCAGGCTAACCGGGTCGATACCAGTTGCATCGCGTACGTCAACCTTGTGCAGGTT
GCGCGCAGCCAGGAACAGGTTTTCGTCCAGCTCACCGGTGATGATCAGCACATCTTCCAG
AGCCATGTCTTTCAGTTTCTGTGCCAGCAGCTTAGTTTTCGGCGCTTCTACAGAGAACTT
CTCGACAACGATCAGACGATCCTGACGTACCAGTTCGGACAGGATGCTTTTCAGCGCGCC
GCGGTACATCTTCTTGTTAACTTTTTGACTGTGGTCCTGCGGACGAGCAGCAAAGGTCAC
GCCACCAGAACGCCAGATCGGGCTCTTGATAGAACCAGAACGCGCACGGCCGGTGCCTTT
CTGGCGCCACGGTTTTTTACCGGAACCAGTTACTTCAGCACGAGTCTTCTGAGCACGAGT
ACCCTGACGAGCACCAGCTGCATAAGCAACAACAACCTGGTGAACCAGCGCTTCGTTGAA
ATCACGACCGAAGGTAGTTTCGGAAACAGTCAGCGCGCTCTGCGCGTCTTTCAATACTAA
TTCCAT

# Drug_Target_3_General_Function:
Involved in structural constituent of ribosome

# Drug_Target_3_General_References:
11206551	Perna NT, Plunkett G 3rd, Burland V, Mau B, Glasner JD, Rose DJ, Mayhew GF, Evans PS, Gregor J, Kirkpatrick HA, Posfai G, Hackett J, Klink S, Boutin A, Shao Y, Miller L, Grotbeck EJ, Davis NW, Lim A, Dimalanta ET, Potamousis KD, Apodaca J, Anantharaman TS, Lin J, Yen G, Schwartz DC, Welch RA, Blattner FR: Genome sequence of enterohaemorrhagic Escherichia coli O157:H7. Nature. 2001 Jan 25;409(6819):529-33.
11258796	Hayashi T, Makino K, Ohnishi M, Kurokawa K, Ishii K, Yokoyama K, Han CG, Ohtsubo E, Nakayama K, Murata T, Tanaka M, Tobe T, Iida T, Takami H, Honda T, Sasakawa C, Ogasawara N, Yasunaga T, Kuhara S, Shiba T, Hattori M, Shinagawa H: Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 and genomic comparison with a laboratory strain K-12. DNA Res. 2001 Feb 28;8(1):11-22.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
4238

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
22087

# Drug_Target_3_Name:
50S ribosomal protein L4

# Drug_Target_3_Number_of_Residues:
201

# Drug_Target_3_PDB_ID:
1P86

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00573	Ribosomal_L4

# Drug_Target_3_Protein_Sequence:
>50S ribosomal protein L4
MELVLKDAQSALTVSETTFGRDFNEALVHQVVVAYAAGARQGTRAQKTRAEVTGSGKKPW
RQKGTGRARSGSIKSPIWRSGGVTFAARPQDHSQKVNKKMYRGALKSILSELVRQDRLIV
VEKFSVEAPKTKLLAQKLKDMALEDVLIITGELDENLFLAARNLHKVDVRDATGIDPVSL
IAFDKVVMTADAVKQVEEMLA

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Forms part of the polypeptide exit tunnel (By similarity)

# Drug_Target_3_SwissProt_ID:
P60725

# Drug_Target_3_SwissProt_Name:
RL4_ECO57

# Drug_Target_3_Synonyms:
Not Available

# Drug_Target_3_Theoretical_pI:
10.45

# Drug_Target_3_Transmembrane_Regions:
None

#END_DRUGCARD DB00199
